BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 ...Middle East

PR Newswire - News
BERGEN, Norway, Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated clinical data from two Phase II studies of bemcentinib in acute myeloid...

Hence then, the article about bergenbio presents updated clinical data from two phase ii studies of bemcentinib in aml and mds patients at ash 2020 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News